Novo Nordisk
NVO
902 hedge funds and large institutions have $15.2B invested in Novo Nordisk in 2022 Q1 according to their latest regulatory filings, with 84 funds opening new positions, 299 increasing their positions, 304 reducing their positions, and 61 closing their positions.
38% more first-time investments, than exits
New positions opened: 84 | Existing positions closed: 61
32% more call options, than puts
Call options by funds: $186M | Put options by funds: $141M
2% more funds holding
Funds holding: 887 → 902 (+15)
3% more capital invested
Capital invested by funds: $14.7B → $15.2B (+$496M)
0.69% more ownership
Funds ownership: 14.87% → 15.56% (+0.69%)
0% more funds holding in top 10
Funds holding in top 10: 23 → 23 (0)
2% less repeat investments, than reductions
Existing positions increased: 299 | Existing positions reduced: 304
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jennison Associates
New York
|
+$499M |
| 2 |
BlackRock
New York
|
+$161M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
+$60M |
| 4 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
+$56.1M |
| 5 |
VIP
Vantage Investment Partners
Kansas City,
Missouri
|
+$50.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
F
Folketrygdfondet
Oslo Norway,
Norway
|
-$405M |
| 2 |
ClearBridge Investments
New York
|
-$142M |
| 3 |
Renaissance Technologies
New York
|
-$75.2M |
| 4 |
Capital International Investors
Los Angeles,
California
|
-$33.6M |
| 5 |
Two Sigma Advisers
New York
|
-$29.8M |
NVO Hedge Fund Activity: Q1 2022 in Review
902 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Novo Nordisk (NVO) for Q1 2022, worth a combined $15.2B — up 3.4% from $14.7B a quarter earlier.
Buyers outnumbered sellers: 84 funds opened new NVO positions and 61 closed out — a net gain of 23 holders — while 299 added to existing stakes and 304 trimmed.
The largest buyer was Jennison Associates, adding an estimated $499M. The largest seller was Folketrygdfondet, cutting an estimated $405M.
- 902 institutional investors held Novo Nordisk (NVO) as of Q1 2022, up from 887 in Q4 2021.
- Funds reported $15.2B of Novo Nordisk stock for Q1 2022, up 3.4% quarter-over-quarter.
- 84 funds opened new Novo Nordisk positions in Q1 2022 and 61 closed out, a net change of +23 holders.
- The largest Novo Nordisk buyer in Q1 2022 was Jennison Associates, an estimated $499M added.
- The largest Novo Nordisk seller in Q1 2022 was Folketrygdfondet, an estimated $405M sold.
Based on aggregated 13F filings for Q1 2022.